Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVES: YKL-40, a growth factor of connective tissue cells, is elevated in sera from patients with diseases characterized by inflammation, tissue remodelling, or fibrosis. The aim of the study was to determine serum YKL-40 levels in patients with systemic sclerosis (SSc) and to explore any possible clinical and prognostic associations.

METHODS: YKL-40 was measured in sera from 88 patients with SSc (26 with diffuse and 62 with limited skin involvement) and in sera from 88 matched healthy controls. Immunohistochemical staining for YKL-40 antigen was performed in a biopsy from a patient with pulmonary SSc.

RESULTS: Serum YKL-40 levels of the SSc patients were significantly higher than those of the controls (p<0.00001). Patients with pulmonary fibrosis by chest X-ray, obstructive ventilatory pattern, reduced diffusing capacity (DLco), and digital joint deformity due to skin retraction had significantly higher serum YKL-40 compared with patients without these findings. Patients with elevated serum YKL-40 had shorter survival times than patients with normal serum YKL-40 (p = 0.0005), although this was not independent of age and pulmonary function. YKL-40 protein expression was found in inflammatory cells in fibrosing pulmonary tissue from a patient with SSc.

CONCLUSIONS: Serum YKL-40 is elevated in patients with SSc with pulmonary involvement.
Original languageEnglish
JournalScandinavian Journal of Rheumatology
Issue number4
Pages (from-to)293-297
Number of pages5
Publication statusPublished - 2005

    Research areas

  • Adipokines, Adult, Age Factors, Aged, Aged, 80 and over, Biological Markers, Case-Control Studies, Cohort Studies, Disease Progression, Female, Glycoproteins, Humans, Lectins, Male, Middle Aged, Probability, Prognosis, Proportional Hazards Models, Pulmonary Fibrosis, Reference Values, Respiratory Function Tests, Risk Assessment, Scleroderma, Systemic, Sensitivity and Specificity, Severity of Illness Index, Sex Factors, Statistics, Nonparametric, Survival Analysis

ID: 32557206